Inferra AIResearch Tools

Inferra AI / Company / ATRC

AtriCure, Inc.

ATRC · Health Care

Last earnings Jul 23, 2026

Key results

Worldwide revenuequarter

17.1%

Worldwide revenue of $136.1 million an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Revenuequarter

$136.1 million

Second Quarter 2025 Financial Results Revenue for the second quarter 2025 was $136.1 million, an increase of 17.1% over second quarter 2024 revenue (16.5% on a constant currency basis), reflecting continued adoption of our products and therapies globally for the treatment of Afib, LAA management and post-operative pain management.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

revenue was $110.6 million, an increase of $15.0 million or 15.7%, compared to the second quarter 2024.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

International revenuequarter

23.3%

International revenue increased $4.8 million or 23.3% (19.9% on a constant currency basis) to $25.6 million, realizing significant growth across all franchises and geographic regions.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Gross marginquarter

74.5%

Gross margin was 74.5% for the second quarter 2025, a decrease of 15 basis points from the second quarter 2024, reflecting less favorable geographic and product mix.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

AI analysis

Q2 2025 · reported Jul 29, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q2 2025
$136.1M
EX-99 · Jul 29, 2025
Gross margin · Q2 2025
74.5%
EX-99 · Jul 29, 2025

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Jul 29, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ2 2025Prior qtrYear ago
Worldwide revenue17.1%——
Revenue$136.1 million——
International revenue23.3%——
Gross margin74.5%——

EX-99 · Jul 29, 2025

Guidance · company-stated

Direction: Raised

Revenue$136.1 million

“htm EX-99.1 Document Exhibit 99.1 For immediate release July 29, 2025 AtriCure Reports Second Quarter 2025 Financial Results Raises Financial Outlook for 2025 Worldwide revenue of $136.1 million an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial MASON, Ohio, July 29, 2025 AtriCure, Inc.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Gross margin74.5%

Capital allocation

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment.

BORROWINGS AND FINANCING OBLIGATION Asset backed revolving credit facility.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 For immediate release July 29, 2025 AtriCure Reports Second Quarter 2025 Financial Results Raises Financial Outlook for 2025 Worldwide revenue of $136.1 million an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial MASON, Ohio, July 29, 2025 AtriCure, Inc.”

Revenue — Raised (“Raises”)
“htm EX-99.1 Document Exhibit 99.1 For immediate release July 29, 2025 AtriCure Reports Second Quarter 2025 Financial Results Raises Financial Outlook for 2025 Worldwide revenue of $136.1 million an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million an increase of $7.6 million year over year Generated $17.9 million of cash in the quarter Completed enrollment of all 6,500 patients in the ground-breaking LeAAPS trial MASON, Ohio, July 29, 2025 AtriCure, Inc.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

BORROWINGS AND FINANCING OBLIGATION Asset backed revolving credit facility.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

The Company has an asset-based credit facility (Credit Agreement) with JPMorgan Chase Bank, N.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

The Credit Agreement provides a $ 125,000 asset-based revolving credit facility (ABL Facility), and the Company may request an increase in the revolving commitment up to $ 40,000 (not to exceed a total of $ 165,000 ).

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

The First Amendment provides a three-year extension of the term of the Credit Agreement, and all outstanding borrowings are due upon the maturity of the Credit Agreement on January 9, 2029.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Following closing, the Company paid down $ 865 of borrowings.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Strategy & priorities

Further, management uses adjusted EBITDA for both strategic and annual operating planning.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Simultaneously, the Company entered into a contract to lease back the existing building and real property, as well as the planned building expansion space from the buyer-lessor.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

The buyer-lessor is financing the development and construction of the expansion of additional manufacturing and office space.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

During construction of the expansion, the Company will maintain occupancy and pay rent for the existing building.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Expansion rental payments are projected to be $ 38,469 for the fifteen-year lease term and are expected to begin during the second half of 2026.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Risks & headwinds

Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ( SEC ), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025, and our quarterly reports on Form 10-Q.

SEC original ↗AtriCure, Inc. — Earnings release (8-K exhibit)EX-99Jul 29, 2025

Legal Proceedings 23 Item 1A.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

The Company may, from time to time, become a party to legal proceedings which are subject to many uncertainties.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Litigation and administrative proceedings over patent and other intellectual property rights are common in our industry, as are requests for information related to interactions with medical professionals.

SEC original ↗AtriCure, Inc. — 10-Q Quarterly report10-QJul 27, 2026

Documents

Earnings deck slides

0 decks with slide view

AtriCure, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

30 documents

Earnings releases

14 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for AtriCure, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.